A mathematical model of tumor-immune evasion and siRNA treatment
From MaRDI portal
Publication:1430340
DOI10.3934/dcdsb.2004.4.39zbMath1083.37531MaRDI QIDQ1430340
Denise E. Kirschner, Trachette L. Jackson, Julia C. Arciero
Publication date: 27 May 2004
Published in: Discrete and Continuous Dynamical Systems. Series B (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.3934/dcdsb.2004.4.39
37N25: Dynamical systems in biology
34C60: Qualitative investigation and simulation of ordinary differential equation models
92C99: Physiological, cellular and medical topics
37C45: Dimension theory of smooth dynamical systems
Related Items
Tractable Model of Malignant Gliomas Immunotherapy with Discrete Time Delays, MATHEMATICAL MODELING OF IN-VIVO TUMOR-IMMUNE INTERACTIONS FOR THE CANCER IMMUNOTHERAPY USING MATURED DENDRITIC CELLS, A NEW MATHEMATICAL MODELING AND SUB-OPTIMAL CHEMOTHERAPY OF CANCER, On a discrete model of tumour–immune system interactions with blockade of immune checkpoints, Dynamics of a Mathematical Model of Cancer and Immunoediting Scenarios Under the Variation of the Immune Cell Activation Rate, Optimization therapy by coupling intermittent androgen suppression with impulsive chemotherapy for a prostate cancer model, STOCHASTIC DYNAMICS BETWEEN THE IMMUNE SYSTEM AND CANCER CELLS WITH ALLEE EFFECT AND IMMUNOTHERAPY, A model of tumor‐immune system interactions with healthy cells and immunotherapies, Global asymptotic stability of a delay differential equation model for SARS-CoV-2 virus infection mediated by ACE2 receptor protein, Studying the importance of regulatory T cells in chemoimmunotherapy mathematical modeling and proposing new approaches for developing a mathematical dynamic of cancer, Analysis of the dynamics of a tumor-immune system with chemotherapy and immunotherapy and quadratic optimal control, Stability and bifurcation analysis of delay induced tumor immune interaction model, A cancer treatment based on synergy between anti-angiogenic and immune cell therapies, Modeling the treatment of glioblastoma multiforme and cancer stem cells with ordinary differential equations, Qualitative and computational analysis of a mathematical model for tumor-immune interactions, Modelling lymphoma therapy and outcome, Diffusive tumor-immune interaction systems under immunotherapy, A structural methodology for modeling immune-tumor interactions including pro- and anti-tumor factors for clinical applications, On immunotherapies and cancer vaccination protocols: a mathematical modelling approach, Ultimate dynamics of the Kirschner-Panetta model: tumor eradication and related problems, A mathematical model of treatment of cancer stem cells with immunotherapy, Methods for determining key components in a mathematical model for tumor-immune dynamics in multiple myeloma, The four-dimensional Kirschner-Panetta type cancer model: how to obtain tumor eradication?, Tumour suppression by immune system through stochastic oscillations, Modeling anti-tumor Th1 and Th2 immunity in the rejection of melanoma, Bounding the dynamics of a chaotic-cancer mathematical model, Bridging blood cancers and inflammation: the reduced cancitis model, Dynamical behaviour of a tumor-immune system with chemotherapy and optimal control, A mathematical model of the enhancement of tumor vaccine efficacy by immunotherapy, The dynamical behaviors for a class of immunogenic tumor model with delay, A mathematical model of tumor-immune interactions, Stability and Hopf bifurcations in a competitive tumour-immune system with intrinsic recruitment delay and chemotherapy, Existence and bifurcation of non-constant positive steady states for a tumor-immune model, Nonlinear dynamics in tumor-immune system interaction models with delays, Modeling the stem cell hypothesis: investigating the effects of cancer stem cells and TGF \(- \beta\) on tumor growth, Optimal control for cancer treatment mathematical model using Atangana-Baleanu-Caputo fractional derivative, Mathematical modeling of tumor and cancer stem cells treated with CAR-T therapy and inhibition of TGF-\(\beta\), A chaos study of tumor and effector cells in fractional tumor-immune model for cancer treatment, Mathematical modelling for the role of CD\(4^+\)T cells in tumor-immune interactions, Existence of periodic solution for a tumor growth model with vaccine interaction, A cellular automata model of tumor-immune system interactions, Global stability and tumor clearance conditions for a cancer chemotherapy system, New observations on optimal cancer treatments for a fractional tumor growth model with and without singular kernel, A fractional-order delay differential model with optimal control for cancer treatment based on synergy between anti-angiogenic and immune cell therapies, Complex dynamics of a tumor-immune system with antigenicity, Optimal control of variable-order fractional model for delay cancer treatments, A mathematical model of tumor-immune interactions with an immune checkpoint inhibitor, Cancer-induced immunosuppression can enable effectiveness of immunotherapy through bistability generation: a mathematical and computational examination, A stochastic individual-based model to explore the role of spatial interactions and antigen recognition in the immune response against solid tumours, Pattern formation in a nonlocal mathematical model for the multiple roles of the TGF-\(\beta\) pathway in tumour dynamics, A mathematical model of combined \textit{bacillus Calmette-Guerin} (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer, Modeling pancreatic cancer dynamics with immunotherapy, Dynamics of tumor-\( \text{CD}4^+\)-cytokine-host cells interactions with treatments, A set-valued approach to control immunotherapy, Interactions between the immune system and cancer: A brief review of non-spatial mathematical models, Mathematical modeling on helper T cells in a tumor immune system, Stochastic hybrid automata with delayed transitions to model biochemical systems with delays, A Feedback Control Model of Comprehensive Therapy for Treating Immunogenic Tumours, A Mathematical Model of Gene Therapy for the Treatment of Cancer, Dual role of delay effects in a tumour–immune system, Evolutionary paradigm in cancer immunology